Biomarkers for Alzheimer’s disease

References

• Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord.15, 169–173 (2001).
   PubMed Web of Science ®Google Scholar
• Giannakopoulos P, Herrmann FR, Bussière T et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology60, 1495–1500 (2003).
   PubMed Web of Science ®Google Scholar
• Nagy Z, Esiri MM, Jobst KA et al. Relative roles of plaques and tangles in the dementia of Alzheimer’s disease: correlations using three sets of neuropathological criteria. Dementia6, 21–31 (1995).
   PubMedGoogle Scholar
• Haroutunian V, Purohit DP, Perl DP et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol.56, 713–718 (1999).
   PubMedGoogle Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment clinical characterisation and outcome Arch. Neurol.56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet.39(1), 17–23 (2007).
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Han X, Tanimura Y et al. Effects of human apolipoprotein E isoforms on the amyloid β-protein concentration and lipid composition in brain low-density membrane domains. J. Neurochem.101(4), 949–958 (2007).
   PubMedGoogle Scholar
• Wilkins MR, Pasquali C, Appel RD et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology1, 61–65 (1996).
   Google Scholar
• Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17, 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Steen H, Pandey A. Proteomics goes quantitative: measuring protein abundance. Trends Biotechnol.9, 361–364 (2002).
   Google Scholar
• Heck AJ, Krijgsveld J. Mass spectrometry-based quantitative proteomics. Expert Rev. Proteomics3, 317–326 (2004).
   Google Scholar
• Kuhn K, Thompson A, Prinz T et al. Isolation of N-terminal protein sequence tags from cyanogen bromide cleaved proteins as a novel approach to investigate hydrophobic proteins. J. Proteome Res.6, 598–609 (2003).
   Google Scholar
• Thompson A, Schäfer J, Kuhn K et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem.75, 1895–1904 (2003).
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics12, 1154–1169 (2004).
   Google Scholar
• Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer’s disease. Electrophoresis23, 2247–2251 (2002).
   PubMed Web of Science ®Google Scholar
• Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res.118(1–2), 140–146 (2003).
   PubMedGoogle Scholar
• Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurol. Res.28, 155–163 (2006).
   PubMed Web of Science ®Google Scholar
• Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers21, 93–101 (2005).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport13, 611–615 (2002).
   PubMed Web of Science ®Google Scholar
• Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann. Neurol.61, 120–129 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang R, Barker L, Pinchev D et al. Mining biomarkers in human sera using proteomic tools. Proteomics4, 244–256 (2004).
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics3, 1486–1494 (2003).
   PubMed Web of Science ®Google Scholar
• Huang JT, Leweke FM, Oxley D et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med.11, E428 (2006).
   Google Scholar
• Selle H, Lamerz J, Bueger K et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer’s disease. Comb. Chem. High Throughput Screen.8, 801–806 (2005).
   PubMed Web of Science ®Google Scholar
• Todaro L, Puricelli L, Gioseffi H et al. Neural cell adhesion molecule in human serum. Increased levels in dementia of the Alzheimer type. Neurobiol. Dis.15, 387–393 (2004).
   PubMedGoogle Scholar
• Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain129, 3042–3050 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis.8(4), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis.9, 293–348 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics.(4), 573–588 (2006).
   Google Scholar
• Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids(3–4), 419–425 (2003).
   Google Scholar
• Butterfield DA, Castegna A. Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: insights into neurodegeneration. Cell. Mol. Biol.5, 747–751 (2003).
   Google Scholar
• Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res.1000(1–2), 1–7 (2004).
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Hasegawa M, Takio K et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem.270, 823–829 (1995).
   PubMed Web of Science ®Google Scholar
• Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer’s disease brain using nanoelectrospray mass spectrometry. J. Neurochem.71, 2465–2476 (1998).
   PubMed Web of Science ®Google Scholar
• Dettmer K, Hammock BD. Metabolomics – a new exciting field within the ‘omics’ sciences. Environ. Health Perspect.112(7) 396–397 (2004).
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. Suppl.114(Suppl. 185), 43–49 (2006).
   Google Scholar
• Hartai Z, Juhasz A, Rimanoczy A et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer’s disease. Neurochem. Int.50(2), 308–313 (2007).
   PubMed Web of Science ®Google Scholar
• Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev.52(2), 201–243 (2006).
   PubMed Web of Science ®Google Scholar
• Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann. Neurol.58(4), 623–626 (2005).
   PubMedGoogle Scholar
• Montine TJ, Neely MD, Quinn JF et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med.33(5), 620–666 (2002).
   PubMed Web of Science ®Google Scholar
• Montine TJ, Quinn JF, Milatovic D et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann. Neurol.52(2), 175–179 (2002).
   PubMed Web of Science ®Google Scholar
• Klunk WE, Panchalingam K, Moosy J, McClure RJ, Pettegrew JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer’s disease brain: a preliminary proton nuclear magnetic resonance study. Neurology42, 1578–1585 (1992).
   PubMed Web of Science ®Google Scholar
• Miller BL, Moats RA, Shonk T, Earnst T, Wooley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology187, 433–437 (1993).
   PubMed Web of Science ®Google Scholar
• Huang W, Alexander GE, Chang L et al. Brain metabolite concentration and dementia severity in Alzheimer’s disease. A 1H MRS study. Neurology57, 626–632 (2001).
   PubMedGoogle Scholar
• Valenzuela MJ, Sachdev PS, Wen W, Shnier R, Brodaty H, Gillies D. Dual voxel proton magnetic resonance spectroscopy in the healthy elderly: subcortical-frontal axonal N-acetylaspartate levels are correlated with fluid cognitive abilities independent of structural brain changes. Neuroimage12, 747–756 (2000).
   PubMedGoogle Scholar
• Thulborn K, Martin C, Voyvodic J. Functional MR imaging using a visually guided saccade paradigm for comparing activation patterns in patients with probable Alzheimer’s disease and in cognitively able elderly volunteers. Am. J. Neuroradiol.21, 524–531 (2000).
   PubMed Web of Science ®Google Scholar
• Kantarci K, Jack CR Jr. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease. NeuroRx2, 196–205 (2004).
   Google Scholar
• Benveniste H, Einstein G, Kim KR, Hulette C, Johnson A. Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy. Proc. Natl Acad. Sci. USA96, 14079–14084 (1999).
   PubMedGoogle Scholar
• Poduslo JF, Wengenack TM, Curran GL et al. Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhancing magnetic resonance imaging. Neurobiol. Dis.11, 315–329 (2002).
   PubMed Web of Science ®Google Scholar
• Bacskai BJ, Frosch MP, Freeman SH et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch. Neurol.64(3), 431–434 (2007).
   PubMed Web of Science ®Google Scholar
• Verhoeff NP, Wilson AA, Takeshita S et al. In vivo imaging of Alzheimer disease β-amyloid with (11C)SB-13 PET Am. J. Geriatr. Psychiatry12, 584–595 (2004).
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can. J. Psychiatr. Nurs.52(3), 146–157 (2007).
   Google Scholar
• Rabinovici GD, Furst AJ, O’Neil JP et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology68, 1205–1212 (2007).
   PubMed Web of Science ®Google Scholar
• Rowe CC, Ng S, Ackermann U et al. Imaging β-amyloid burden in aging and dementia. Neurology68(20), 1718–1725 (2007).
   PubMed Web of Science ®Google Scholar
• The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging working group. Consensus report on: molecular and biochemical markers of Alzheimer’s disease. Neurobiol. Aging19, 109–116 (2003).
   Google Scholar
• Frank RA, Galasko D, Hampel H et al. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging24(4), 521–536 (2003).
   PubMed Web of Science ®Google Scholar